Our work now suggests that also directly targeting PLA2G4A may hold therapeutic potential, as demonstrated by the comparable growth-delaying effect of AACOCF3 on murine H9M cells as well as on human AML lines with recombined MLL (Figure 5 and Figure 6A). The gene discussed is KMT2A; the disease is acute myeloid leukemia.